A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma

Trial Profile

A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma

Completed
Phase of Trial: Phase 0

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Astrocytoma; Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Sep 2017 Status changed from recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 24 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top